Thiogenesis Therapeutics (TSXV:TTI) Pre-Tax Income : C$-4.09 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Thiogenesis Therapeutics's pretax income for the three months ended in Sep. 2024 was C$-0.66 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was C$-4.09 Mil. Thiogenesis Therapeutics's pretax margin was %.

Thiogenesis Therapeutics Pre-Tax Income Historical Data

The historical data trend for Thiogenesis Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Pre-Tax Income Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Pre-Tax Income

-0.07

-0.61

-0.09

-0.22

-5.06

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial											-1.06	-2.07	-0.71	-0.65	-0.66

Competitive Comparison of Thiogenesis Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Thiogenesis Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Thiogenesis Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Thiogenesis Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-5.206	+	-0.028	+	0	+	0.171	+	0
	=	-5.06

Thiogenesis Therapeutics's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.678	+	-0.028	+	0	+	0.049	+	0
	=	-0.66

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.09 Mil.

Thiogenesis Therapeutics (TSXV:TTI) Pre-Tax Income Explanation

Thiogenesis Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.657	/	0
	=	%

Thiogenesis Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder